Cholangiocarcinoma Trial – Learn about a phase II multi-center study evaluating combination immunotherapy for advanced cholangiocarcinoma (bile duct cancer) with pembrolizumab and Sylatron (peginterferon alfa-2b): HCRN GI16-263…
Shared Information improves and Galvanises our Outcomes
What do you think about this video ? can you recommend a video? We welcome your comments?
As a patient-led foundation, we specialise in offering patient-integrated support, response solutions, and strategies for those affected by Cholangiocarcinoma. We actively collaborating with scientific researchers, healthcare professionals, and industry leaders, to improve today’s patient outcomes and survival rates – Read More –
Our North Star: Empower the Patient – Increase Survival: Empower their community – Exponentially Increase Survivorship.
The Empowered Patient is uniquely positioned and equipped to understand, engage, and succeed by utilizing a process that integrates scientific advancements, evidence-based medicine, and human resilience attributes into a comprehensive response strategy.
Fully embracing the concept of an empowered patient will advance science, reshape the healthcare response, and close the unattended gap between early detection and late-stage diagnosis.